Literature DB >> 25692724

Patient and disease factors affecting the choice and adherence to active surveillance.

Marc A Dall'Era1.   

Abstract

PURPOSE OF REVIEW: Treatment decisions for low-risk prostate cancer are arguably some of the most challenging in oncology. Active surveillance has emerged as an important option for many men with tumors estimated to have a low metastatic potential. Multiple complex patient and physician factors affect the recommendation, selection, and adherence to active surveillance. While baseline clinical criteria are used to identify candidates for this approach, it is important to identify and understand other forces that may influence the management of prostate cancer with active surveillance. RECENT
FINDINGS: Patient perceptions and acceptance of active surveillance have improved over time. Treatment decisions for prostate cancer are strongly associated with physician recommendations, and a high-quality relationship between the patient and his healthcare system is critical to successful active surveillance. Patient understanding of prostate cancer and consistency of information received from separate physicians can affect a decision to pursue active surveillance. Psychological symptoms, most notably regarding anxiety and distress, can affect adherence to active surveillance over time. In general, anxiety for men on active surveillance is low, and lifestyle interventions and self-management strategies may be helpful for increasing quality of life and limiting abandonment of active surveillance in the absence of disease progression.
SUMMARY: Multiple factors may affect the decision for and adherence to active surveillance for prostate cancer. It is important for both physicians and patients to be aware of these issues and work towards individualized approaches and interventions as needed to increase adoption of active surveillance in the future.

Entities:  

Mesh:

Year:  2015        PMID: 25692724     DOI: 10.1097/MOU.0000000000000154

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  12 in total

1.  Balancing Confounding and Generalizability Using Observational, Real-world Data: 17-gene Genomic Prostate Score Assay Effect on Active Surveillance.

Authors:  Steven Canfield; Michael J Kemeter; Phillip G Febbo; John Hornberger
Journal:  Rev Urol       Date:  2018

2.  Patients' Knowledge, Beliefs, and Distress Associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey.

Authors:  Marc R Freiman; Jack A Clark; Christopher G Slatore; Michael K Gould; Steven Woloshin; Lisa M Schwartz; Renda Soylemez Wiener
Journal:  J Thorac Oncol       Date:  2016-03-07       Impact factor: 15.609

3.  Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer.

Authors:  Richard M Hoffman; Tania Lobo; Stephen K Van Den Eeden; Kimberly M Davis; George Luta; Amethyst D Leimpeter; David Aaronson; David F Penson; Kathryn Taylor
Journal:  Med Decis Making       Date:  2019-10-21       Impact factor: 2.583

4.  What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.

Authors:  Samuel Borofsky; Arvin K George; Sonia Gaur; Marcelino Bernardo; Matthew D Greer; Francesca V Mertan; Myles Taffel; Vanesa Moreno; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2017-10-20       Impact factor: 11.105

5.  Prostate cancer management choices in patients undergoing multiparametric magnetic resonance imaging/ultrasound fusion biopsy compared to systematic biopsy.

Authors:  Jennifer B Gordetsky; Benjamin Saylor; Sejong Bae; Jeffrey W Nix; Soroush Rais-Bahrami
Journal:  Urol Oncol       Date:  2018-03-08       Impact factor: 2.954

Review 6.  Quality of life in active surveillance and the associations with decision-making-a literature review.

Authors:  Julia Menichetti; Riccardo Valdagni; Lara Bellardita
Journal:  Transl Androl Urol       Date:  2018-02

7.  Describing perspectives of health care professionals on active surveillance for the management of prostate cancer.

Authors:  Kittie Pang; Margaret Fitch; Veronique Ouellet; Simone Chevalier; Darrel E Drachenberg; Antonio Finelli; Jean-Baptiste Lattouf; Alan So; Simon Sutcliffe; Simon Tanguay; Fred Saad; Anne-Marie Mes-Masson
Journal:  BMC Health Serv Res       Date:  2018-06-08       Impact factor: 2.655

8.  Attitude towards active surveillance: a cross-sectional survey among patients with uroandrological disorders.

Authors:  Paolo Capogrosso; Luca Boeri; Eugenio Ventimiglia; Ilenya Camozzi; Walter Cazzaniga; Francesco Chierigo; Roberta Scano; Alberto Briganti; Francesco Montorsi; Andrea Salonia
Journal:  BMJ Open       Date:  2018-08-29       Impact factor: 2.692

9.  Patient Factors That Influence How Physicians Discuss Active Surveillance With Low-Risk Prostate Cancer Patients: A Qualitative Study.

Authors:  Joanna Veazey Brooks; Shellie D Ellis; Emily Morrow; Kim S Kimminau; J Brantley Thrasher
Journal:  Am J Mens Health       Date:  2018-07-04

10.  Self-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy.

Authors:  William E Grizzle; Rick A Kittles; Soroush Rais-Bahrami; Ebony Shah; George W Adams; Mark S DeGuenther; Peter N Kolettis; Jeffrey W Nix; James E Bryant; Ravi Chinsky; James E Kearns; Kerry Dehimer; Norma Terrin; Hong Chang; Sandra M Gaston
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.